CEO Robert Ford has said the atrial fibrillation treatment, along with the company’s Volt PFA device, is expected to help Abbott regain market share in electrophysiology.
CEO Robert Ford has said the atrial fibrillation treatment, along with the company’s Volt PFA device, is expected to help Abbott regain market share in electrophysiology.